Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ELI LILLY & CoLLY · Entity 2794 | EVP & Pres, Lilly Neuroscience | February 10, 2025 | February 12, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ELI LILLY & Co
Report date February 10, 2025 · Filed February 12, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 74,209.769 |
Reported balance
After 2025-02-10 transaction · row 1
1 source rowRow 1 · 2025-02-10 · Grant · Acquired 6,828.871 · Balance 74,209.769 |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Expires 2026-02-01 | Direct | 3,572 |
Reported balance
After 2025-02-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-02-10 · Grant · Acquired 3,572 · Balance 3,572 F1: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 10, 2025 Filed Feb 12, 2025 21:29 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantRestricted Stock Unit · Derivative | 3,572 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-25-000059 · wk-form4_1739395756.xml · derivative · entry 2 White Anne E. · CIK 0001752313 · EVP & Pres, Lilly Neuroscience 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,572 Underlying: Common Stock · 3,572 shares Expires 2026-02-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 10, 2025 Filed Feb 12, 2025 21:29 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 6,828.871 | $868.88 | $5,933,469.43 |
DisclosureSEC source: 0000059478-25-000059 · wk-form4_1739395756.xml · nonDerivative · entry 1 White Anne E. · CIK 0001752313 · EVP & Pres, Lilly Neuroscience 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,209.769 Read SEC document |
| February 01, 2025 Filed Feb 4, 2025 21:27 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionRestricted Stock Unit · Derivative | 3,269 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-25-000032 · wk-form4_1738704436.xml · derivative · entry 3 White Anne E. · CIK 0001752313 · EVP & Pres, Lilly Neuroscience 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,269 shares Expires 2025-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 01, 2025 Filed Feb 4, 2025 21:27 UTC | ELI LILLY & Co LLY · Entity 2794 | Tax withholdingCommon Stock | 1,457.102 | $811.08 | $1,181,826.29 |
DisclosureSEC source: 0000059478-25-000032 · wk-form4_1738704436.xml · nonDerivative · entry 2 White Anne E. · CIK 0001752313 · EVP & Pres, Lilly Neuroscience 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,380.898 Read SEC document |
| February 01, 2025 Filed Feb 4, 2025 21:27 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionCommon Stock | 3,269 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-25-000032 · wk-form4_1738704436.xml · nonDerivative · entry 1 White Anne E. · CIK 0001752313 · EVP & Pres, Lilly Neuroscience 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,838 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 21:44 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantRestricted Stock Unit · Derivative | 3,269 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-24-000062 · wk-form4_1707947068.xml · derivative · entry 2 White Anne E. · CIK 0001752313 · EVP & Pres, Lilly Neuroscience 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,269 Underlying: Common Stock · 3,269 shares Expires 2025-02-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 21:44 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 5,363 | $737.26 | $3,953,925.38 |
DisclosureSEC source: 0000059478-24-000062 · wk-form4_1707947068.xml · nonDerivative · entry 1 White Anne E. · CIK 0001752313 · EVP & Pres, Lilly Neuroscience 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,569 Read SEC document |
| February 01, 2024 Filed Feb 2, 2024 21:20 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionRestricted Stock Unit · Derivative | 4,124 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-24-000013 · wk-form4_1706908818.xml · derivative · entry 3 White Anne E. · CIK 0001752313 · EVP & Pres, Lilly Neuroscience 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,124 shares Expires 2024-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 01, 2024 Filed Feb 2, 2024 21:20 UTC | ELI LILLY & Co LLY · Entity 2794 | Tax withholdingCommon Stock | 1,844 | $645.61 | $1,190,504.84 |
DisclosureSEC source: 0000059478-24-000013 · wk-form4_1706908818.xml · nonDerivative · entry 2 White Anne E. · CIK 0001752313 · EVP & Pres, Lilly Neuroscience 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,206 Read SEC document |
| February 01, 2024 Filed Feb 2, 2024 21:20 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionCommon Stock | 4,124 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-24-000013 · wk-form4_1706908818.xml · nonDerivative · entry 1 White Anne E. · CIK 0001752313 · EVP & Pres, Lilly Neuroscience 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,050 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 13, 2023 Filed Feb 14, 2023 22:12 UTC | ELI LILLY & Co LLY · Entity 2794 | SaleCommon Stock | 2,500 | $346.47 | $866,175.00 |
DisclosureSEC source: 0000059478-23-000069 · wf-form4_167641273108663.xml · nonDerivative · entry 3 White Anne E. · CIK 0001752313 · EVP & Pres, Lilly Neuroscience 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,926 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 2, 2022. Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 22:12 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantRestricted Stock Unit · Derivative | 4,124 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-23-000069 · wf-form4_167641273108663.xml · derivative · entry 4 White Anne E. · CIK 0001752313 · EVP & Pres, Lilly Neuroscience 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,124 Underlying: Common Stock · 4,124 shares Expires 2024-02-01 F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 22:12 UTC | ELI LILLY & Co LLY · Entity 2794 | SaleCommon Stock | 2,500 | $342.76 | $856,900.00 |
DisclosureSEC source: 0000059478-23-000069 · wf-form4_167641273108663.xml · nonDerivative · entry 2 White Anne E. · CIK 0001752313 · EVP & Pres, Lilly Neuroscience 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,426 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 2, 2022. Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 22:12 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 8,562 | $345.12 | $2,954,917.44 |
DisclosureSEC source: 0000059478-23-000069 · wf-form4_167641273108663.xml · nonDerivative · entry 1 White Anne E. · CIK 0001752313 · EVP & Pres, Lilly Neuroscience 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,926 Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 22:04 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionRestricted Stock Unit · Derivative | 7,264 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-23-000043 · wf-form4_167546185628642.xml · derivative · entry 3 White Anne E. · CIK 0001752313 · EVP & Pres, Lilly Neuroscience 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,264 shares Expires 2023-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 22:04 UTC | ELI LILLY & Co LLY · Entity 2794 | Tax withholdingCommon Stock | 3,252 | $344.15 | $1,119,175.80 |
DisclosureSEC source: 0000059478-23-000043 · wf-form4_167546185628642.xml · nonDerivative · entry 2 White Anne E. · CIK 0001752313 · EVP & Pres, Lilly Neuroscience 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,364 Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 22:04 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionCommon Stock | 7,264 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-23-000043 · wf-form4_167546185628642.xml · nonDerivative · entry 1 White Anne E. · CIK 0001752313 · EVP & Pres, Lilly Neuroscience 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,616 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 09, 2022 Filed Feb 11, 2022 23:38 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantRestricted Stock Unit · Derivative | 7,264 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-22-000056 · wf-form4_164462270168794.xml · derivative · entry 2 White Anne E. · CIK 0001752313 · SVP & Pres-Lilly Neuroscience 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,264 Underlying: Common Stock · 7,264 shares Expires 2023-02-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 09, 2022 Filed Feb 11, 2022 23:38 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 11,348 | $243.27 | $2,760,627.96 |
DisclosureSEC source: 0000059478-22-000056 · wf-form4_164462270168794.xml · nonDerivative · entry 1 White Anne E. · CIK 0001752313 · SVP & Pres-Lilly Neuroscience 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,352 Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 22:09 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionRestricted Stock Unit · Derivative | 9,368 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-22-000032 · wf-form4_164392615619605.xml · derivative · entry 3 White Anne E. · CIK 0001752313 · SVP & Pres-Lilly Neuroscience 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,368 shares Expires 2022-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 22:09 UTC | ELI LILLY & Co LLY · Entity 2794 | Tax withholdingCommon Stock | 4,204 | $245.39 | $1,031,619.56 |
DisclosureSEC source: 0000059478-22-000032 · wf-form4_164392615619605.xml · nonDerivative · entry 2 White Anne E. · CIK 0001752313 · SVP & Pres-Lilly Neuroscience 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,004 Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 22:09 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionCommon Stock | 9,368 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-22-000032 · wf-form4_164392615619605.xml · nonDerivative · entry 1 White Anne E. · CIK 0001752313 · SVP & Pres-Lilly Neuroscience 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,208 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 08, 2021 Filed Feb 11, 2021 01:48 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantRestricted Stock Unit · Derivative | 9,368 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-21-000066 · wf-form4_161300810149825.xml · derivative · entry 2 White Anne E. · CIK 0001752313 · SVP & Pres-Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,368 Underlying: Common Stock · 9,368 shares Expires 2022-02-01 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 08, 2021 Filed Feb 11, 2021 01:48 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 4,718 | $205.77 | $970,822.86 |
DisclosureSEC source: 0000059478-21-000066 · wf-form4_161300810149825.xml · nonDerivative · entry 1 White Anne E. · CIK 0001752313 · SVP & Pres-Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,840 Read SEC document |
| February 11, 2020 Filed Feb 13, 2020 23:19 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 7,079 | $144.25 | $1,021,145.75 |
DisclosureSEC source: 0000059478-20-000048 · wf-form4_158163596956610.xml · nonDerivative · entry 1 White Anne E. · CIK 0001752313 · SVP & Pres-Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,122 Read SEC document |
| October 25, 2019 Filed Oct 28, 2019 19:11 UTC | ELI LILLY & Co LLY · Entity 2794 | PurchaseCommon Stock | 1,000 | $108.84 | $108,840.00 |
DisclosureSEC source: 0000059478-19-000289 · wf-form4_157228979250811.xml · nonDerivative · entry 1 White Anne E. · CIK 0001752313 · SVP & Pres-Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,043 Read SEC document |
| February 04, 2019 Filed Feb 7, 2019 00:53 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 7,246 | $120.17 | $870,751.82 |
DisclosureSEC source: 0000059478-19-000065 · wf-form4_154950080990103.xml · nonDerivative · entry 1 White Anne E. · CIK 0001752313 · SVP & Pres-Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,043 Read SEC document |
| December 02, 2018 Filed Dec 4, 2018 20:14 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionRestricted Stock Unit · Derivative | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-18-000286 · wf-form4_154395442914579.xml · derivative · entry 3 White Anne E. · CIK 0001752313 · SVP & Pres-Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,500 shares Expires 2018-12-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| December 02, 2018 Filed Dec 4, 2018 20:14 UTC | ELI LILLY & Co LLY · Entity 2794 | Tax withholdingCommon Stock | 3,306 | $118.64 | $392,223.84 |
DisclosureSEC source: 0000059478-18-000286 · wf-form4_154395442914579.xml · nonDerivative · entry 2 White Anne E. · CIK 0001752313 · SVP & Pres-Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,797 Read SEC document |
| December 02, 2018 Filed Dec 4, 2018 20:14 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionCommon Stock | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-18-000286 · wf-form4_154395442914579.xml · nonDerivative · entry 1 White Anne E. · CIK 0001752313 · SVP & Pres-Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,103 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.